{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-301044","form_type":"8-K","ticker":"BNTC","cik":"0001808898","company_name":"Benitec Biopharma Inc.","filed_at":"2022-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.239370+00:00","generated_at":"2026-06-21T07:39:42.317074+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Benitec shareholders reject preferred stock authorization at 2022 annual meeting","bullets":["Proposal 5 to authorize 5M shares of preferred stock failed; all other proposals passed.","Directors Jerel Banks and Megan Boston elected with ~98% of votes cast (excluding broker non-votes).","Shareholders approved increase in authorized common stock, reverse stock split, and advisory say-on-pay.","Ratification of independent auditor (BDO USA) received 18.7M for, 137k against, 118k abstain.","Broker non-votes on four proposals totaled 5.2M shares out of 19.0M present at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-301044","json":"https://secwatch.observer/filing/0001193125-22-301044.json","markdown":"https://secwatch.observer/filing/0001193125-22-301044.md","text":"https://secwatch.observer/filing/0001193125-22-301044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808898/000119312522301044/0001193125-22-301044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808898/000119312522301044/d352118d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T07:39:42.317074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f15c99f8645d854309e2cdd0c692f4b74b776bf","claim":"Benitec Biopharma Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2022-12-07 meeting.","evidence_excerpt":"Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm. The results were as follows: For Against Abstain 18,739,378 137,128 117,650","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808898/000119312522301044/0001193125-22-301044-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"b1476e83d9df9afb624e106a798d4ad219098b9c","claim":"Benitec Biopharma Inc. shareholders approved Approval of an Amendment to the Company's Certificate of Incorporation to Effect a Reverse Stock Split of the Company's Common Stock at the 2022-12-07 meeting.","evidence_excerpt":"Proposal 6 – Approval of an Amendment to the Company’s Certificate of Incorporation to Effect a Reverse Stock Split of the Company’s Common Stock. The results were as follows: For Against Abstain 17,463,834 1,528,782 1,540","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808898/000119312522301044/0001193125-22-301044-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"b5be7165e6fb867545aa8f9f8bec23ad1530a301","claim":"Benitec Biopharma Inc. shareholders approved Advisory Vote on Executive Compensation at the 2022-12-07 meeting.","evidence_excerpt":"Proposal 3 – Advisory Vote on Executive Compensation. The results were as follows: For Against Abstain Broker Non-Vote 13,411,245 396,016 14,487 5,172,408","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808898/000119312522301044/0001193125-22-301044-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"cbf29d3a3c5d33c04894245e1dcd91cccccabd35","claim":"Benitec Biopharma Inc. shareholders rejected Approval of an Amendment to the Company's Certificate of Incorporation to Authorize the Issuance of Up to 5,000,000 Shares of Preferred Stock at the 2022-12-07 meeting.","evidence_excerpt":"Proposal 5 – Approval of an Amendment to the Company’s Certificate of Incorporation to Authorize the Issuance of Up to 5,000,000 Shares of Preferred Stock. The results were as follows: For Against Abstain Broker Non-Vote 12,501,121 1,316,881 3,746 5,172,408","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808898/000119312522301044/0001193125-22-301044-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"failed"},{"label":"Meeting","value":"2022-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"e2846ce1b0ee20ad236f6d76346349c4fac097b5","claim":"Benitec Biopharma Inc. shareholders approved Approval of an Amendment to the Company's Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock at the 2022-12-07 meeting.","evidence_excerpt":"Proposal 4 – Approval of an Amendment to the Company’s Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock. The results were as follows: For Against Abstain 15,970,145 2,906,409 117,602","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808898/000119312522301044/0001193125-22-301044-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"e383311da4b6f7d2cf73160648d975bec5118104","claim":"Benitec Biopharma Inc. shareholders approved Approval of the Adjournment of the Annual Meeting, if Necessary, to Solicit Additional Proxies at the 2022-12-07 meeting.","evidence_excerpt":"Proposal 7 – Approval of the Adjournment of the Annual Meeting, if Necessary, to Solicit Additional Proxies. The results were as follows: For Against Abstain 15,968,583 2,905,589 119,984","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808898/000119312522301044/0001193125-22-301044-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"fbd9a19d49173bcc9fd1751bfca4e0b1deab377f","claim":"Benitec Biopharma Inc. shareholders approved Election of Directors at the 2022-12-07 meeting.","evidence_excerpt":"Proposal 1 – Election of Directors . The results were as follows: Director Nominee For Withhold Broker Non-Votes Dr. Jerel Banks 13,564,345 257,403 5,172,408 Megan Boston 13,528,333 293,415 5,172,408","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808898/000119312522301044/0001193125-22-301044-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-07"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}